Medication-assisted Treatment (MAT) Market Size

Medication-assisted Treatment (MAT) Market size was valued at USD 10.42 billion in 2024 and is expected to reach USD 31.19 billion by 2037, expanding at around 8.8% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of medication-assisted treatment is assessed at USD 11.2 billion.

This can be attributed to the rising prevalence of substance use disorder among individuals. According to recent information, around 286 Million people aged 15-64 used drugs worldwide in 2020, a 26 percent increase over the past decade.

In addition, with the advancement in medications and therapies such as the availability of a variety of medications like methadone, naltrexone. There is a continuous improvement in behavioral therapies and pharmacological treatments which is enhancing the efficacy of medication-assisted treatment. Moreover, the development of long-acting formulations and innovative delivery methods is also driving the medication-assisted treatment market growth.

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of medication-assisted treatment is assessed at USD 11.2 billion.

The medication-assisted treatment market size was valued at USD 10.42 billion in 2024 and is expected to reach USD 31.19 billion by 2037, expanding at around 8.8% CAGR during the forecast period i.e., between 2025-2037. Increase in substance abuse deaths, rising awareness of medication-assisted treatment and emergence of technological innovations will drive the market growth.

North America industry is likely to account for largest revenue share of 45% by 2037, impelled by surging funding by government for the MAT initiatives in the region

The major players in the market are Orexo AB, Novartis AG, Mylan N.V., Lupin Limited, Hikma Pharmaceuticals PLC and others.

Medication-assisted Treatment (MAT) Market Size